BriaCell Therapeutics Corp.
NASDAQ Capital MarketTotal Valuation
BriaCell Therapeutics Corp. carries a market capitalization of 31.06M, placing it among publicly traded companies globally. Its enterprise value stands at 27.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 31.06M |
| Enterprise Value | 27.43M |
Share Statistics
BriaCell Therapeutics Corp. currently has 655,809.00 shares outstanding.
| Shares Outstanding | 655,809.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.25 |
| P/TBV Ratio | 3.30 |
| P/FCF Ratio | -0.70 |
| P/OCF Ratio | -0.70 |
Financial Position
BriaCell Therapeutics Corp. maintains a current ratio of 3.41, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -656.21 |
Financial Efficiency
| Return on Equity (ROE) | -490.69 |
| Return on Assets (ROA) | -167.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BriaCell Therapeutics Corp.'s stock has declined approximately -53.75648% over the past 52 weeks. The 50-day moving average sits at 3.57, while the 200-day moving average is 4.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | -53.75648% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 4.83 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -24.27M, while operating income came in at -24.42M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -24.42M |
| Pretax Income | -19.64M |
| Net Income | -19.43M |
| EBITDA | -24.27M |
| EBIT | -24.42M |
| Earnings Per Share (EPS) | -71.80 |
Balance Sheet
Total book value stands at 12.42M, with working capital of 10.45M providing operational flexibility.
| Cash & Cash Equivalents | 12.46M |
| Total Debt | N/A |
| Net Debt | -12.46M |
| Equity (Book Value) | 12.42M |
| Book Value Per Share | 18.93 |
| Working Capital | 10.45M |
Cash Flow
BriaCell Therapeutics Corp. produced -24.07M in operating cash flow over the past twelve months.
| Operating Cash Flow | -24.07M |
| Capital Expenditures | N/A |
| Free Cash Flow | -24.07M |
| FCF Per Share | -88.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -89.96 |
| FCF Yield | -142.99 |
Stock Splits
BriaCell Therapeutics Corp.'s most recent stock split took place on August 25, 2025 with a 10:1 split ratio.
| Last Split Date | 8/25/2025 |
| Split Ratio | 10:1 |
Scores
BriaCell Therapeutics Corp. posts an Altman Z-Score of -7.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.89 |